Lenacapavir represents a significant advancement in HIV prevention, with the potential to help end the epidemic if accessibility is prioritized.
A subscription pricing model could be a viable solution to ensure that those in need can obtain this critical treatment without prohibitive costs.
This approach may also stabilize supply chains and enhance overall healthcare infrastructure, allowing for more efficient distribution and utilization of resources.